Part 1 Why invest in Generex GNBT, a development stage company with a poor financial statement?
Why invest in Generex GNBT, a development stage company with a poor financial statement?
By: Gary Mishler 3-8-14
Here are the reasons that I am investing:
1. They have developed an Antigen, which concentrates on developing proprietary vaccine formulations that work by stimulating the immune system to either attack offending agents (i.e., cancer cells, bacteria, and viruses). This is huge, being able to target a specific diseased cell and having our own immune system attack and kill it! No drugs with harmful side effects to pump into the body. This is the way medicine should be. Studies to date show that it is safe and effective, no negatives to date. “The added potency of Antigen Express vaccines derives from its ability to activate CD4+ T helper cells, which are critical in the generation of a novel immune response.”
2. Patent Office approval for the applications for the use of therapeutic vaccines targeting human papilloma virus (HPV) caused cancers as well as to potentially pandemic strains of influenza virus. (Per P R Newswire dated 3-5-2014) Receiving these patents is gigantic, because this alone gives GNBT the exclusive rights to the process! This will allow GNBT the ability to negotiate with other companies that want to use this technology to pay up for the right through agreements with GNBT. That means future funding and joint venture agreements with major pharmaceutical companies and possible milestone payments. They own the process now.
3. Low downside risk, the stock has been severely beaten down from its highs at this point. It has taken time to get the patent approval; now that they have it I see only upside from here. The price per share is so low that you can scoop up a bucket full of shares for a few dollars. There is a large short in the stock that must now be worried after the approval by the patent office and they are out in force bashing the stock. Thanks to their work you can pick up these shares at the rock bottom price of .04 c / share.
4. The charts look favorable as well, years of a long down trend followed by a long one year sideways movement with strong support being established and in January 2014 has just started an uptrend. Once the public learns the facts as they are now, the shorts will be squeezed. There are Penny Stock newsletters that are looking at this stock at this moment. All it takes is one of them to recommend the stock and you could see a 1,000% to 4,000% move up.
5. Future news and publications, In May 2014, GNBT will publish in the journal Human Vaccines and Immunotherapeutics that: “ In a separate Phase II trial of AE37 in patients with early stage breast cancer, it has been observed that patients with lower levels of HER2 expression appear to benefit most from AE37 immunization. AE37 is designed to elicit an immune response to the HER2 protein, which is expressed at varying levels in tumors of the breast, prostate, ovarian, gastro-intestinal tract, and a variety of other cancers.”